At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 148 enrolled
Drug / intervention
Teneli (Teneligliptin) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV Study of Teneligliptin (MP-513) in Combination With Insulin in Japanese Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 4 clinical trial evaluating Teneli (Teneligliptin), Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 148 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of Teneligliptin in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration and to evaluate the safety and efficacy of Teneligliptin in combination with Insulin with an extension treatment for up to 52 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedMar 2014
Primary CompletionJan 2016
TodayJul 2026
First PostedMar 7, 2014
Enrollment StartJan 1, 2014
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.3 years ago
Interventions
Teneli (Teneligliptin)drug
Placebodrug
Insulindrug